Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Third-Generation EGFR Tyrosine Kinase Inhibitor

J Thorac Oncol. 2017 Nov;12(11):e181-e182. doi: 10.1016/j.jtho.2017.07.017.

Authors

Alessandra Bearz¹, Elisa De Carlo², Roberto Doliana³, Monica Schiappacassi³

Affiliations

¹ Department of Clinical Oncology, Centro di riferimento oncologico Aviano National Cancer Institute, Aviano, Pordenone, Italy.
² Department of Clinical Oncology, Centro di riferimento oncologico Aviano National Cancer Institute, Aviano, Pordenone, Italy. Electronic address: elisa.decarlo@cro.it.
³ Experimental Oncology Department, Centro di riferimento oncologico Aviano National Cancer Institute, Aviano, Pordenone, Italy.

PMID: 29074209
DOI: 10.1016/j.jtho.2017.07.017

No abstract available

Publication types

Letter
Comment

MeSH terms

Acrylamides
Aniline Compounds
ErbB Receptors / antagonists & inhibitors
Humans
Lung Neoplasms / genetics*
Mutation
Piperazines
Proto-Oncogene Proteins B-raf / antagonists & inhibitors*

Substances

Acrylamides
Aniline Compounds
Piperazines
osimertinib
EGFR protein, human
ErbB Receptors
BRAF protein, human
Proto-Oncogene Proteins B-raf